Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EOLS
EVOLUS, INC.
NASDAQ
$8.88
▲ UP 0.00% (0.00)

KEY STATISTICS

Market Cap$584.79 M
52w High$9.12
52w Low$3.86
Dividend Yield—
Frequency—
P/E-28.12
Volume1.06M
Shares Out.65.85M

COMPANY

LEADERSHIP

David Moatazedi
CHIEF EXECUTIVE
David Moatazedi

COMPENSATION 2026

Salary$775,000
Stock Awards$3,886,569
Incentive Plan Pay$429,000
All Other Comp.$24,948
Total$6,412,214

ABOUT

SECTOR
Healthcare
WENT PUBLIC
February 8, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
353

PRICE TARGET

Target High$27.00
Target Low$13.00
Target Median$17.00
Target Consensus$18.40

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$77.78M
NOV
4
WED

PRICE

$8.88 ▲ UP 0.00% (+$0.00)
$8.60$8.70$8.80$8.909:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM8.88

About Evolus, Inc.

https://www.evolus.com ↗

Evolus, Inc. is a performance beauty company based in Newport Beach, California, offering medical aesthetic products like Jeuveau, a botulinum toxin for temporary wrinkle reduction in adults.

INDUSTRY

Drug Manufacturers - Specialty & Generic

A PRODUCT EVOLUS, INC. IS KNOWN FOR

Evolysse
Evolysse

Evolysse, launched in April 2025, is a hyaluronic acid dermal filler for moderate to severe facial wrinkles, expanding Evolus’s portfolio alongside Jeuveau as part of its growth strategy.

COMPETITORS

COMPETITOR
ABBV COMPARE
ANIK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$68.97M $89.22M ▲$72.75M ▼$83.35M ▲
Service— $1.08M $390K ▼$734K ▲

Revenue by Geography

MapREGIONQ3-2020Q2-2021Q1-2022
CANADA$738K $702K ▼$682K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
76
LISTED HERE
11
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.5M
XSU.TO
0.02% · 1.5M
XPH
0.63% · 415.0K
XWEH.F
0.02% · 395.9K
SCHA
0.01% · 306.2K
GSSC
0.08% · 101.2K
RSSL
0.02% · 28.2K
PILL
0.42% · 11.7K
IBBQ
0.04% · 4.1K
URTY
0.01% · 2.4K
RESM
0.02% · 160

INSTITUTIONAL OWNERSHIP

SHARES OWNED
64.73%
HOLDERS
253
TOP 12 OF 253 · RANKED BY POSITION SIZE
Nantahala Capital Management, LLC
6.4M sh · $26.21M
Tang Capital Management LLC
5.5M sh · $33.7M
Blackrock, Inc.
4.8M sh · $33.6M
Caligan Partners LP
4.1M sh · $25.41M
Blackrock Inc.
4.0M sh · $43.49M
Vanguard Group Inc
3.4M sh · $21.05M
Braidwell LP
3.2M sh · $21.9M
Frazier Life Sciences Management, L.P.
2.6M sh · $18.26M
Perceptive Advisors LLC
2.5M sh · $17.07M
Soleus Capital Management, L.P.
2.2M sh · $9.23M
Millennium Management LLC
2.1M sh · $13.92M
Stonepine Capital Management, LLC
1.8M sh · $7.23M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: SEE REMARKS
Avelar Rui
Sale · 3.1K shares
2026-03-20
★
DIRECTOR, OFFICER: SEE REMARKS
MOATAZEDI DAVID
Sale · 13.7K shares
2026-03-20
★
DIRECTOR, OFFICER: SEE REMARKS
MOATAZEDI DAVID
Sale · 67.5K shares
2026-03-16
★
OFFICER: SEE REMARKS
Avelar Rui
Purchase · 8.8K shares
2026-03-16

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
HOLD 1
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY BTIG BUY Stifel BUY Needham HOLD Mizuho OUTPERFORM

SECTORS PEERS

PEERPRICE
SLDB$9.77COMPARE
CBLL$23.73COMPARE
AUTL$2.34COMPARE
KIDS$23.65COMPARE
NGNE$36.58COMPARE
KMDA$8.29COMPARE
TMCI$4.65COMPARE
QSI$0.78COMPARE